The Rycroft Health clinical research team are actively supporting research into more effective treatments to help better manage patients with asthma. As part of their research work, our clinical research team are carrying out FeNO testing on eligible patients registered with Spring Hall Group Practice, Halifax, West Yorkshire. We are delighted to be partnering with the Bradford Institute for Health Research and Sanofi in the delivery of this study. We are also grateful to BIHR who have supported the delivery of this FeNO testing through access to the BIHR's mobile research facility.

FeNO (Fractional Exhaled Nitric Oxide) testing is a quick, non-invasive breath test that measures inflammation in the airways, primarily used to help diagnose and manage asthma, especially to identify eosinophilic inflammation which responds well to corticosteroids. Patients breathe steadily into the FeNO device, and the result indicates the level on inflammation within the lungs, helping doctors tailor asthma treatment and monitor its effectiveness. It's a simple alternative to more complex lung function tests.